DSM-Firmenich stock after-hours at EUR 98.14: minus 1.41 percent
Published on 09/29/2026 at 21:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DSM-Firmenich stock was EUR 98.14 after-hours at 9:05 p.m. CEST on September 29, 2026, down EUR 1.40, or 1.41 percent, versus the EUR 99.54 prior close at Lang & Schwarz.
Biond portfolio launched for biopharma applications
On September 29, dsm-firmenich announced the launch of Biond, a portfolio of pharmaceutical-grade vitamins designed for cell culture media and biologics manufacturing. The company said the offering is available globally and exclusively through Brenntag Pharma’s BYPHAR biopharma product portfolio. Biond is scheduled to debut at CPHI Milan from October 6 through October 8, according to the dsm-firmenich release.
Share repurchases reported
dsm-firmenich said it repurchased 313,835 ordinary shares between September 21 and September 25 at an average price of EUR 96.45 per share, for a total of EUR 30.3 million. The company said its EUR 500 million program to reduce issued capital was intended to be completed by the end of the third quarter. The figures were reported in the company’s share repurchase update.
